Orexigen Defines A Way To Get The Contrave PDUFA Clock Ticking
This article was originally published in The Pink Sheet Daily
Executive Summary
The summary report of an interim analysis of the ongoing LIGHT clinical trial evaluating the cardiovascular safety of the obesity medicine can form the basis of a resubmission of the Contrave NDA, the company announced, shaving some time off the PDUFA clock.